Live Vital Review: 156 Studies on One Page, None on the Product Pages

What the registry actually says about these molecules

The claims are not fabrications. They describe real mechanisms drawn from real literature. The question this site asks is narrower: does the evidence reach as far as the sentence does?

For BPC-157, the human registry record sits at phase 1. ¹ Phase 1 asks whether a dose is tolerated. It cannot answer whether tissue heals faster, whether blood vessels form, or whether a gut lining repairs — which are the three things the product page asserts. The animal literature behind those assertions is substantial and it is animal literature; nothing on the page marks that line.

TB-500's own registry record is also phase 1, and recruiting. ² The broader thymosin beta-4 programme is further along, but thymosin beta-4 is a different molecule from the fragment being sold, and the page moves between them without saying so.

MOTS-c has a phase 2 trial that is recruiting, not reporting. ⁴ "Activates the AMPK pathway" is accurate. "Make your metabolism work harder, even without changing your diet" is a promise about outcomes, and the trial that might one day support it has not finished enrolling.

The CJC-1295 and ipamorelin literature is phase 2 and concerns growth hormone release. ³ The page leads with "most patients notice they're sleeping differently within the first two weeks" — a claim about incidence and timing, which is the shape of a trial result, offered without one.

Where the claims are good

It is worth being precise about what Live Vital gets right, because it is unusual.

Its semaglutide page says: "In the STEP-1 trial, adults without diabetes taking semaglutide for weight management lost an average of roughly 15% of their body weight over 68 weeks." Every element of that is correct. STEP 1 randomised 1,961 adults to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. ⁵ The population is correctly described, the figure is right, the duration is right, and the trial is named rather than gestured at with "clinical studies show".

Its tirzepatide page does the same with SURMOUNT-1 — 2,539 participants, 72 weeks, roughly 20% at the highest dose. ⁶ Also correct.

That is a higher standard than most of this category reaches, and it makes the contrast with the peptide pages sharper rather than softer. The company clearly knows how to attach a claim to a trial. It does it for the two molecules that have trials, and not for the ones that do not.

The sentence you are asked to sign

Live Vital's peptide-therapy consent contains this, verbatim:

"I acknowledge that Live Vital is not responsible for any manufacturing issues related to peptides prepared by compounding pharmacies and that the sole responsibility for sterility, potency, and safety lie with these pharmacies."

That is a reasonable division of responsibility. A telehealth platform does not compound anything, and saying so is honest.

It only works, though, if the reader can identify the pharmacy. And Live Vital never names one. Across 26 pages it says "503A-licensed pharmacies", "all 503A pharmacies that Live Vital partners with", "a licensed US compounding pharmacy" — always plural, always anonymous.

So the consent moves responsibility for sterility and potency onto a party, and the site withholds that party's identity. If a lot were wrong, the document you signed tells you whose problem it is and the website tells you nothing about how to reach them.

No certificate of analysis is published either — no batch record, no potency result, no sterility result, no named laboratory, for any product. The FAQ says the peptide "undergoes testing" at the pharmacy. That is a claim about the unnamed party, made by the party that has disclaimed responsibility.

Two shelf-life claims that outrun the pharmacy

The FAQ states that "the pharmacy and our doctors say that the medication and its potency are good for 6 months after opening. Many patients use it longer with no issues."

And, more directly: "BUDs are set 90 days from the last day of compounding… although the reality is that most peptides are stable and safe if refrigerated for over 180 days."

A beyond-use date is the compounding pharmacy's own limit on how long its preparation can be relied upon. The second sentence acknowledges that limit is 90 days and then tells the reader the real number is double it. That advice comes from the company that has, in its consent form, assigned potency to somebody else.

What this means if you are buying

For semaglutide or tirzepatide, the claims on these pages are accurate and better attributed than most. Check the price arithmetic — a 10-week protocol advertised as "$X/mo" is divided by three months when ten weeks is 2.31, so the real monthly cost is about 30% above the figure shown.

For any of the peptides, the questions to settle before paying are the ones the site does not answer: which 503A pharmacy compounds it, whether that lot was tested and by whom, and what evidence stands behind the sentence that persuaded you. Live Vital has 156 study summaries that speak to the last one. It has simply never put a link to them where you would look.